FindTrial
Sign In

To observe the effect of vitreous injection of ranibizumab (3+PRN ) and different administration methods of ranibizumab combined with dexamethasone intravitreal implant in the treatment of macular edema secondary to retinal vein occlusion

To observe the effect of vitreous injection of ranibizumab (3+PRN ) and different administration methods of ranibizumab combined with dexamethasone intravitreal implant in the treatment of macular edema secondary to retinal vein occlusion

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060835
Enrollment
Unknown
Registered
2022-06-12
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy

Interventions

1:Vitreous injection of ramizumab
2:Vitreous injection of ramizumab and dexamethasone

Sponsors

Shandong Eye Hospital Ethics Committee
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Adults aged 18 or older; 2.Diagnosis of ME secondary to RVO proven by clinical examination , CMT on OCT >250 µm; 3.Followed up for at least 6 months after treatment.

Exclusion criteria

Exclusion criteria: 1.Patients received intravitreal drug injection therapy within 3 months or had a history of systemic glucocorticoid use; 2.Those who have had intraocular surgery other than cataract surgery; 3.OCT suggested the presence of macular membrane or vitreous macular traction; 4.Patients with history of other eye diseases that affect vision,including diabetic; retinopathy,glaucoma,maculopathy,uveitis etc.; 5.Patients with other diseases that can cause macular edema; 6.Patients who were lost to follow-up during the study period.

Design outcomes

Primary

MeasureTime frame
Best Corrected Visual Acuity;Central Retinal Thickness;—

Countries

China

Contacts

Public ContactJingjing Zhang
vitreo_retina@126.com+86 15965633553

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026